Creative Financial Designs’s Editas Medicine EDIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-40
Closed -$297 1668
2024
Q1
$297 Hold
40
﹤0.01% 1613
2023
Q4
$405 Hold
40
﹤0.01% 1547
2023
Q3
$312 Hold
40
﹤0.01% 1457
2023
Q2
$329 Hold
40
﹤0.01% 1428
2023
Q1
$290 Hold
40
﹤0.01% 1358
2022
Q4
$355 Hold
40
﹤0.01% 1250
2022
Q3
$0 Hold
40
﹤0.01% 1294
2022
Q2
$0 Hold
40
﹤0.01% 1262
2022
Q1
$1K Hold
40
﹤0.01% 1201
2021
Q4
$1K Hold
40
﹤0.01% 1162
2021
Q3
$2K Hold
40
﹤0.01% 1298
2021
Q2
$2K Hold
40
﹤0.01% 1319
2021
Q1
$2K Hold
40
﹤0.01% 1205
2020
Q4
$3K Hold
40
﹤0.01% 1069
2020
Q3
$1K Hold
40
﹤0.01% 1148
2020
Q2
$1K Buy
+40
New +$1.04K ﹤0.01% 1091
2019
Q4
Sell
-100
Closed -$2.5K 558
2019
Q3
$2K Hold
100
﹤0.01% 547
2019
Q2
$2K Hold
100
﹤0.01% 508
2019
Q1
$2K Sell
100
-100
-50% -$2.26K ﹤0.01% 496
2018
Q4
$5K Hold
200
﹤0.01% 428
2018
Q3
$6K Hold
200
﹤0.01% 497
2018
Q2
$7K Hold
200
﹤0.01% 502
2018
Q1
$7K Hold
200
﹤0.01% 454
2017
Q4
$6K Hold
200
﹤0.01% 473
2017
Q3
$5K Sell
200
-100
-33% -$1.9K ﹤0.01% 501
2017
Q2
$5K Hold
300
﹤0.01% 518
2017
Q1
$7K Buy
+300
New +$6.22K 0.01% 441

Other funds holding EDIT

Creative Financial Designs's EDIT Position: Q2 2024 in Review

Creative Financial Designs sold out of Editas Medicine (EDIT) in Q2 2024, closing a stake of 40 shares — an estimated $297 sold.

Creative Financial Designs first reported a position in EDIT in Q1 2017 and held it in 27 quarters. The position peaked at $7K in Q2 2018. 235 funds tracked by Wall St. Rank hold EDIT as of Q2 2024.

  • Creative Financial Designs reported no remaining Editas Medicine position as of Q2 2024 after selling out during the quarter.
  • Creative Financial Designs sold 40 Editas Medicine shares in Q2 2024, an estimated $297.
  • Creative Financial Designs first reported a position in Editas Medicine in Q1 2017 and held it in 27 quarters.
  • Creative Financial Designs's Editas Medicine position peaked at $7K in Q2 2018.
  • 235 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2024.

Based on Creative Financial Designs's 13F filing for Q2 2024, filed 6 Aug 2024.